Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование андекаликсимаба у участников с прогрессирующей оссифицирующей фибродисплазией (ФОП) (ANDECAL)

3 ноября 2026 г. обновлено: Ashibio Inc

Фаза 2/3, глобальное, многоцентровое, рандомизированное, двойное слепое, плацебо-контролируемое, двухчастное исследование с открытым расширением (OLE) для оценки эффективности и безопасности андекаликсимаба у участников с прогрессирующей оссифицирующей фибродисплазией (ФОП).

This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP.

The study is looking at several research questions, including:

  • Safety of andecaliximab in participants with FOP
  • Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO)
  • Whether andecaliximab reduces the number or severity of flare-ups
  • Pharmacokinetics/pharmacodynamics (PK/PD): How much study drug is in your blood at different times and its impact on blood biomarker(s)
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Обзор исследования

Подробное описание

The ASH-FOP-201 Study consists of 2 parts: Part 1 is a Lead-in Study to assess safety, PK/PD and preliminary efficacy; Part 2 is the Main Study, a Phase 2/3 randomized, double-blind, placebo-controlled trial.

Part 1 is composed of Part 1a, a Na18F positron emission tomography (PET)/computed tomography, less head (CT) Study in up to 6 participants age ≥ 15 years, and Part 1b, a flare-up Study in up to 6 participants ≥ 12 years of age. Participants enrolled in Part 1 will be randomized to one of two dose levels for 13 weeks. Participants in Part 2 will be randomized to one of two dose levels of drug vs. placebo during the 52 week trial. All participants in Part 1 or Part2 will receive study drug in the extension period of the trial.

Тип исследования

Интервенционный

Регистрация (Оцененный)

92

Фаза

  • Фаза 2
  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

    • California
      • San Francisco, California, Соединенные Штаты, 94143
        • University of California San Francisco (UCSF)
    • Minnesota
      • Rochester, Minnesota, Соединенные Штаты, 55905
        • Mayo Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Соединенные Штаты, 19104
        • University of Pennsylvania - Perelman Center for Advanced Medicine

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

2 года и старше (Ребенок, Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria (Part 1a, 1b, and 2):

  1. Participant and/or guardian able and willing to give informed consent and/or assent as applicable, and willing to adhere to the visits schedule and study procedures.
  2. Clinical diagnosis of FOP including congenital malformation(s) consistent with FOP (e.g., of the great toes), and either episodic soft tissue swelling consistent with an FOP flare-up and/or progressive HO.

4. CAJIS score of ≤19. 5. Disease activity within 1 year of screening visit. Disease activity is defined as physician confirmed flare-up like symptoms or clinical progression including newly identified HO or worsening joint function.

6. Able to understand, undergo, and perform all protocol related procedures, including low-dose WBCT-LH scan without sedation. Assistance from a caregiver is allowed.

7. Agree to provide access to all relevant current and historical medical records (including radiographs or radiographic records) and growth records.

Inclusion Criteria (Part 1a only):

  1. Male or female ≥ 15 years of age.
  2. Serum creatinine ≤ upper limit of normal for age.
  3. No open growth plates on bilateral PA hand/wrist or AP knee films at baseline
  4. Able to receive IV radiotracer [both IV access and no history of a reaction to radiotracer].
  5. No use of bisphosphonates or bone active agent within the past year.
  6. At least 1 active HO lesion at baseline per Na18F PET/CT

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 1b only):

  1. Male or female ≥12 years of age.

  2. History of multiple flare-up episodes within the past 6 months (to be reviewed and confirmed as qualifying by the PI together with the Sponsor). Qualifying flare-up episodes include any of the following:

    • At least 3 qualifying flare-ups in the past 6 months each with continuous symptoms for at least 1 week
    • Migratory flare-up swellings across the back
    • Multiple flare-up episodes the sum of which lasted at least 21 days The timing of the individual flare-ups can be overlapping; they may be ongoing at the time of enrollment or resolved.
  3. The qualifying flare-ups must involve at least 2 of the following flare-up symptoms:

    • Pain
    • Soft tissue swelling
    • Warmth
    • Redness
    • Joint stiffness
    • Decreased range of motion

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 2 only):

  1. Initial enrollment age requirement is ≥12 years
  2. Enrollment may be extended to participants ≥6 years of age after safety in adult and participants age 12-17 years has been established.
  3. Enrollment of participants ≥2 to <6 years of age will commence after safety in adult and participants ≥6 years of age has been established.

Additional inclusion criteria apply including those listed above for all parts of the study.

Exclusion Criteria:

  1. Body weight <10kg

  2. Known non-healed fracture at time of Study Day 1.

  3. Planned surgery within the timeframe of the study duration or still recovering from recent surgery.

  4. Respiratory compromise that requires use of supplemental oxygen.

  5. Participant has

    • Known monogenic disorder other than FOP.
    • Bone or mineral disorder unrelated to FOP.
  6. Malignancy (within the past 5 years, except non-melanoma skin cancer, cervical carcinoma in situ, or ductal carcinoma in situ [DCIS]).

  7. Known active infection (including fungal, bacterial, mycobacterial, or viral infection including COVID19)

  8. Uncontrolled hypoparathyroidism or hyperparathyroidism.

  9. Per participant report or chart review (no testing required): Uncontrolled hyperthyroidism

  10. Use of the following medication:

    • Systemic corticosteroids with a prednisone equivalent of >10mg/day within 1 week of Study Day 1. If the participant requires chronic use of >10mg/day prednisone equivalent of corticosteroids, eligibility will be discussed with the Sponsor.
    • NSAIDs of higher than doses recommended by the May 2022 ICCFOP guidelines within 1 week of Study Day 1. If the participant requires chronic use of NSAIDs at doses higher than those recommended by the May 2022 ICCFOP guidelines doses, eligibility will be discussed with the Sponsor.
    • Current or chronic use of tetracycline drugs (e.g., tetracycline, demeclocycline, doxycycline, or minocycline).
  11. Chronic use of any of unproven therapies for FOP.

  12. Palovarotene

    • Within 1 month of Study Day 1 for all participants
    • Within 2 years of Study Day 1 for female participants <8 years of age Or male participants <10 years of age
  13. Treatment with another investigational product within 5 half lives of last dose at the time of Study Day 1 or 1 month, whichever is longer.

  14. History of allergy or hypersensitivity to andecaliximab or its excipients.

  15. Significant current laboratory abnormalities

  16. Breastfeeding, pregnant, or planning pregnancy.

  17. Those of childbearing potential unwilling to agree to abstain from sexual activity that could result in pregnancy or unwillingness to use acceptable birth control during the study and for 90 days after the last dose.

  18. Simultaneous participation in another clinical trial involving another investigational product.

  19. Significant medical condition or disability or biochemical or hematologic abnormalities that in the opinion of the Investigator would expose the participant to undue risk, prevent the conduct of study procedures, or confound the study results.

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Part 1a: PET/CT Study

a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) Study to assess the impact of two dose levels of andecaliximab administered subcutaneously (SC), once-a-week (QW) in participants age ≥ 15 years, with FOP on a number of outcomes including Safety, Pharmacokinetic (PK) and pharmacodynamic (PD) and the change from baseline of Na18F uptake in HO lesions by PET/CT scan, and Patient Reported Outcomes (PROs).

Dose level A or B

Dose level A or B (or age adjusted dose)

Экспериментальный: Part 1b: Flare-up Study

a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) study to assess the impact of two dose levels of andecaliximab administered SC QW in participants ≥12 years of age with a recent history of frequent flare-up episodes on a number of outcomes including safety, PK/PD, and flare-up incidence and symptoms and PROs.

Dose level A or B

Dose level A or B (or age adjusted dose)

Плацебо Компаратор: Part 2: Main Study

1-year (52-week) double-blind (Investigator, participant, and sponsor all blinded), placebo-controlled study of andecaliximab Dose level A or B (or age adjusted) SC QW or placebo in pediatric and adult patients with FOP. The Main Study will enroll approximately 80 participants, randomized in a 1:1:1 ratio to andecaliximab Dose level A or B (or age adjusted) SC QW or placebo.

Dose level A or B

Dose level A or B (or age adjusted dose)

Blinded

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]
Временное ограничение: Week 27 and 53

Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones.

Week 27 and 53

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Изменение объема HO с течением времени по оценке WBCT-LH [Все тело, компьютерная томография (КТ), не включая голову (меньше головы)]
Временное ограничение: Неделя 27 и 53
Неделя 27 и 53
Количество обострений по сообщениям участника
Временное ограничение: Неделя 14, 27 и 53
Неделя 14, 27 и 53
Количество обострений, сообщенных участником и подтвержденных главным исследователем
Временное ограничение: Неделя 14, 27 и 53
Неделя 14, 27 и 53
Percent change from baseline in Na18F standardized uptake value maximum (SUVmax) of up to 7 individual HO lesion(s) per participant active at baseline as assessed by Na18F PET/CT (Part 1a).
Временное ограничение: Week 14

SUV max is the SUV of the most intense voxel within a region of interest.

Week 14
Change in HO volume over time as assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)] (Part 1a)
Временное ограничение: Week 14

Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones. In Part 1a, the WBCT-LH scan will be acquired as part of the PET/CT scan at baseline and Week 14.

Week 14
Number of days during which a flare-up is experienced by the participant as reported by the participant
Временное ограничение: Week 14, 27 and 53

Flare-up defined as having at least two of the following symptoms: pain, soft tissue swelling, warmth, redness, joint stiffness, or decreased range of motion.

Week 14, 27 and 53
Change in patient joint involvement as assessed by Investigator using Cumulative Analog Joint Involvement Scale (CAJIS)
Временное ограничение: Week 27 and 53

CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30.

Week 27 and 53
Change in patient quality of life as assessed by the EuroQol 5 dimensions questionnaire with a 5-level scale (EQ-5D-5L)
Временное ограничение: Week 27 and 53

EQ-5D-5L measures: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

Week 27 and 53
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Временное ограничение: Week 27 and 53

Number of participants with Treatment-Emergent Adverse Events (AE) (TEAEs), i.e., adverse events not present at baseline or exacerbation of a pre-existing condition during the on-treatment period will be reported.

Week 27 and 53
Number of Participants With Serious Treatment-Emergent Adverse Events (Serious TEAEs)
Временное ограничение: Week 27 and 53

Number of participants with Serious Treatment-Emergent Adverse Events (AE) (TEAEs), i.e, required initial/prolonged in-patient hospitalization, death, life-threatening, persistent/significant disability/incapacity, congenital anomaly/birth defect, considered as a medically important event.

Week 27 and 53
Number of Participants With TEAEs by Severity
Временное ограничение: Week 27 and 53

Severity of TEAEs will be graded as follows: Mild: Does not interfere in a significantly with functioning. Moderate: Causes some impairment of functioning but is not hazardous to health. Severe: Significant impairment or incapacitation; hazardous to one's health. Number of participants with TEAEs by severity will be reported.

Week 27 and 53

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

25 октября 2024 г.

Первичное завершение (Оцененный)

4 февраля 2029 г.

Завершение исследования (Оцененный)

4 февраля 2029 г.

Даты регистрации исследования

Первый отправленный

17 июня 2024 г.

Впервые представлено, что соответствует критериям контроля качества

12 июля 2024 г.

Первый опубликованный (Действительный)

18 июля 2024 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

5 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

3 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • ASH-FOP-201

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

Redacted Protocol and SAP will be made available.

Сроки обмена IPD

After completion of the Biologics License Applications (BLA) and all participants have completed the one year extension.

Критерии совместного доступа к IPD

Not decided at this time

Совместное использование IPD Поддерживающий тип информации

  • STUDY_PROTOCOL
  • САП

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться